...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer
【24h】

Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer

机译：评估预测日本非转移性阉割前列腺癌患者疾病进展的因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Despite recent introduction of several novel agents, limited data exist regarding parameters that help predict the progression of non-metastatic castration-resistant prostate cancer (nmCRPC). The objective of this study was to identify prognostic predictors in nmCRPC patients. Patients and Methods: This study included 127 consecutive Japanese nmCRPC patients treated in routine clinical practice. Prognostic outcomes in these patients were analyzed to evaluate the impact of several parameters on prostate-specific antigen progression-free survival (PSA PFS) and metastasis-free survival (MFS). Results: When the 127 patients were diagnosed with nmCRPC, the PSA and PSA doubling time (PSADT) were 13.5 ng/ml and 17.9 months, respectively. Of these, 77 (60.6%) and 50 (39.4%) were treated with first-generation anti-androgen (FGA) and novel androgen-receptor-axis-targeted agent (ARATA), respectively, as first-line therapy for nmCRPC. The median PSA PFS and MFS after the diagnosis of nmCRPC in these patients were 29.5 months and not reached, respectively. Multivariate analyses identified the following independent prognostic factors: PSA at nmCRPC, PSADT and first-line therapy for nmCRPC for PSA PFS, and PSA at nmCRPC and PSADT for MFS. Conclusion: nmCRPC patients with higher PSA and/or shorter PSADT should be treated with ARATA rather than FGA.
机译：背景/目的：尽管最近引入了几种新型代理，存在有关有助于预测非转移性阉割前列腺癌（NMCRPC）的进展的参数的有限数据。本研究的目的是鉴定NMCRPC患者的预后预测因子。患者及方法：本研究包括常规临床实践中连续127名患者治疗的患者。分析了这些患者的预后结果，评估了几种参数对前列腺特异性抗原进展的生存（PSA PFS）和无转移存活率（MFS）的影响。结果：当127名患者被诊断为NMCRPC时，PSA和PSA倍增时间（PSADT）分别为13.5ng / ml和17.9个月。其中77（60.6％）和50（39.4％）分别用第一代抗雄激素（FGA）和新的雄激素受体轴靶向剂（ARATA）作为NMCRPC的一线治疗。在这些患者NMCRPC诊断后的中位PSA PFS和MFS分别为29.5个月，并未达到。多变量分析确定了以下独立的预后因素：NMCRPC的PSA，PSA PFS的PSA PFS的PSA和第一线疗法，以及在NMCRPC和MFS的PSAA的PSA。结论：患有较高PSA和/或更短PSADT的NMCRPC患者应用ARATA而不是FGA治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号